A5079656430- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Glycosylation and Glycoproteins Research
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Biosimilars and Bioanalytical Methods
- Protein purification and stability
- RNA Interference and Gene Delivery
- Bone and Dental Protein Studies
- Immune Cell Function and Interaction
- Cell Adhesion Molecules Research
- Toxin Mechanisms and Immunotoxins
- Viral Infectious Diseases and Gene Expression in Insects
- Cytokine Signaling Pathways and Interactions
- Virus-based gene therapy research
- Cancer Research and Treatments
- Rheumatoid Arthritis Research and Therapies
- Immune Response and Inflammation
- Pharmaceutical studies and practices
- Cancer Immunotherapy and Biomarkers
- Mast cells and histamine
- dental development and anomalies
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
Wenzhou Medical University
2024
Liaocheng University
2013-2024
Jiangsu T-mab BioPharma (China)
2023-2024
Second Military Medical University
2008-2023
National Engineering Research Center for Nanotechnology
2008-2023
Target (United States)
2014-2019
China National Building Materials Group (China)
2017
Luye Pharma (Germany)
2016
Shanghai Cell Therapy Research Institute
2007-2016
Chinese PLA General Hospital
2010-2015
TNFα-targeting therapy with the use of drugs Etanercept, Infliximab, and Adalimumab is used in clinical treatment various inflammatory immune diseases. Although all these reagents function to disrupt interaction between TNFα its receptors, investigations showed advantages compared Etanercept Infliximab. However, underlying molecular mechanism action remains unclear. In our previous work, we presented structural data on how Infliximab binds E-F loop functions as a receptor-binding blocker. To...
There is an urgent need for improved therapy advanced ovarian carcinoma, which may be met by administering immune-modulatory monoclonal antibodies (mAbs) to generate a tumor-destructive immune response. Using the ID8 mouse cancer model, we investigated therapeutic efficacy of various mAb combinations in mice with intraperitoneal (i.p.) tumor established transplanting 3 × 106 cells 10 days previously. While most tested mAbs were ineffective when given individually or together, data confirm...
The host immune system generally serves as a barrier against tumor formation. Programmed death-ligand 1 (PD-L1) is critical "don't find me" signal to the adaptive system, whereas CD47 transmits an anti-phagocytic signal, known eat innate system. These and similar checkpoints are often overexpressed on human tumors. Thus, dual targeting both would likely maximize anti-tumor therapeutic effect elicit more durable responses. Herein, based variable region of atezolizumab consensus variant (CV1)...
CD11c is an antigen receptor predominantly expressed on dendritic cells (DC), to which targeting has been shown induce robust antigen-specific immune responses. To facilitate targeted delivery of tumor antigens DCs, we generated fusion proteins consisting the extracellular domain human HER or its rat homologue neu, fused single-chain fragment variable specific for (scFv(CD11c)-HER2/neu).Induction cellular and humoral responses antitumoral activity admixed with DC-activating CpG...
// Guangchao Li 1,* , Likun Zhao Wei 2,4 Kexing Fan Weizhu Qian 3 Sheng Hou 2,3,4 Hao Wang Jianxin Dai Huafeng and Yajun Guo 1,2,3,4 1 School of Bioscience Bioengneering, South China University Technology, Guangzhou, 2 International Joint Cancer Institute, Second Military Medical University, Shanghai, State Key Laboratory Antibody Medicine & Targeting Therapy Shanghai Cell Engineering Antibody, 4 Pharmacy, Liaocheng Liaocheng, Shandong Provence, * These authors contributed equally to the...
The anti-ErbB2 antibody trastuzumab has shown significant clinical benefits in metastatic breast cancer. However, resistance to is common. Heterodimerization between ErbB2 and other ErbBs may redundantly trigger cell proliferation signals confer resistance. Here, we developed a bispecific using pertuzumab, another ErbB2-specific humanized that binds distinct epitope from trastuzumab. This antibody, denoted as TPL, retained the full binding activities of both parental antibodies exhibited...
Abstract Despite the effectiveness of anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in treatment B-cell lymphoma, its efficacy remains variable and often modest. It seems likely that a combination multiple mechanisms, such as complement-dependent cytotoxicity (CDC) apoptotic signaling, underlies therapeutic success mAbs. Unfortunately, all current mAbs effective CDC are relatively inactive signaling cell death vice versa. In this study, we developed two genetically engineered...
Pregnancy induces a state of immunological tolerance that aims at suppressing immune responses against the fetus and has been linked to temporal remission preexisting autoimmune disorders. To understand mechanisms this reversible regulation, we investigated role key pregnancy hormone, human chorionic gonadotropin (hCG), in type 1 diabetes nonobese diabetic (NOD) mice.We injected hCG into cytokine gene-deficient NOD mice evaluated effects administration on T-cells dendritic cells (DCs).We...
To test the effects of a novel monoclonal antibody (mAb) against human osteopontin (OPN) in prevention and treatment collagen-induced arthritis (CIA) to elucidate underlying mechanisms these effects.DBA/1J mice immunized with type II collagen induce CIA were monitored assess anti-OPN mAb on clinical severity disease, pathologic changes joints examined histologically. The survival activated T cells from arthritic synovial fluid patients rheumatoid (RA) determined by TUNEL assay or annexin V...
The major cause of cancer mortality is the metastatic spread tumor cells that can occur via multiple routes, including vascular system and lymphatic system. In this study, we developed an IgG-like fusion protein molecule [vascular endothelial growth factor (VEGF) receptor 31-immunoglobulin (VEGFR31-Ig)] which could simultaneously bind angiogenic VEGF-A lymphangiogenic VEGF-C. Importantly, VEGFR31-Ig exhibited VEGF-A-binding affinity similar to VEGFTrap, most potent binder, VEGF-C-binding...
// Shi Hu 1, 2, 3, 4, * , Yuna Sun Yanchun Meng 5, 6, 7, Xiaoze Wang 5 Weili Yang Wenyan Fu 4 Huaizu Guo 6 Weizhu Qian Sheng Hou 7 Bohua Li Zihe Rao 3 Zhiyong Lou Yajun 1 International Joint Cancer Institute & Translational Medicine Research Institute, the Second Military Medical University, Shanghai, 200433, P.R. China 2 National Laboratory of Macromolecules, Biophysics, Chinese Academy Science, Beijing, 100101, Structural Biology and MOE Protein School Medicine, Tsinghua 100084, Center,...
CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites. Glycosylation plays vital role in solubility, stability, serum half-life, activity, immunogenicity. For biosimilar development program, comparative analytical data, especially the glycosylation can influence decisions about type amount of animal clinical data needed to establish biosimilarity. Because limited experience with biosimilars before approval, comprehensive level...
Nivolumab, an anti-programmed death (PD)1 IgG4 antibody, has shown notable success as a cancer treatment. Here, we report that nivolumab was susceptible to aggregation during manufacturing, particularly in routine purification steps. Our experimental results showed exposure low pH caused of nivolumab, and the Fc primarily responsible for acid-induced unfolding phenomenon. To compare intrinsic propensity other IgGs subclasses, tocilizumab (IgG1), panitumumab (IgG2) atezolizumab (aglyco-IgG1)...
A pair controlled study was conducted to compare biomechanical properties of antegrade and retrograde nailing humeral fractures. First, six paired fresh anatomic specimen humeri were used the fractured at middle distal diaphyses junction that nailed from approach with Humeral Locked nail those contralateral intact humeri. An 18 additional pairs divided into three equal groups by distal, proximal, or middiaphysis location a standardized 5-mm bone defect simulate unstable The nailings...
Lymphocyte function-associated antigen 1 (LFA-1) plays important roles in immune cell adhesion, trafficking, and activation is a therapeutic target for the treatment of multiple autoimmune diseases. Efalizumab one most efficacious antibody drugs treating psoriasis, very common skin disease, through inhibition binding LFA-1 to ligand intercellular adhesion molecule (ICAM-1). We report here crystal structures Fab alone complex with α L I domain, which reveal molecular mechanism by Efalizumab....